Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors.

[1]  E. Jaffe,et al.  The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. , 1987, The American journal of pathology.

[2]  S. Rosenberg,et al.  Separation and functional studies of the human lymphokine-activated killer cell. , 1987, Cancer research.

[3]  S. Rosenberg,et al.  Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell. , 1987, Natural immunity and cell growth regulation.

[4]  S. Rosenberg,et al.  Clinical effects and toxicity of interleukin‐2 in patients with cancer , 1986, Cancer.

[5]  A. Chang,et al.  High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. , 1986, JAMA.

[6]  D. Longo,et al.  Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. , 1986, Journal of immunology.

[7]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[8]  T. Springer,et al.  Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones , 1986, Nature.

[9]  J. Weinstein,et al.  Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or systemic injection. , 1986, Annals of surgery.

[10]  A. Chang,et al.  A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. , 1986, Surgery.

[11]  S. Rosenberg,et al.  Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. , 1986, Journal of immunology.

[12]  U. Staerz,et al.  Use of anti-receptor antibodies to focus T-cell activity. , 1986, Immunology today.

[13]  A. Balber,et al.  Quantitation and sorting of vitally stained natural killer cell-target cell conjugates by dual beam flow cytometry. , 1986, Cytometry.

[14]  S. Rosenberg,et al.  Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes , 1986 .

[15]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[16]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. , 1985, Journal of immunology.

[17]  J. Bluestone,et al.  Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody , 1985, Nature.

[18]  H. Spits,et al.  Induction of nonspecific cytotoxicity by monoclonal anti-T3 antibodies. , 1985, Journal of immunology.

[19]  R. Reisfeld,et al.  Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells , 1985, The Journal of experimental medicine.

[20]  Osami Kanagawa,et al.  Hybrid antibodies can target sites for attack by T cells , 1985, Nature.

[21]  G. Goodman,et al.  Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Hellstrom,et al.  Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Melamed,et al.  Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Bluestone,et al.  Quantitative measurements of the specificity and kinetics of conjugate formation between cloned cytotoxic T lymphocytes and splenic target cells by dual parameter flow cytometry. , 1985, Journal of Immunology.

[25]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. , 1985, Journal of immunology.

[26]  D. Stephany,et al.  Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies , 1984, The Journal of experimental medicine.

[27]  G. Trinchieri,et al.  Antibody 3G8, specific for the human neutrophil Fc receptor, reacts with natural killer cells. , 1984, Journal of immunology.

[28]  D. Stephany,et al.  The measurement of specific cell: cell interactions by dual-parameter flow cytometry. , 1984, Cytometry.

[29]  R. Reisfeld,et al.  Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Brown,et al.  Studies of a high molecular weight human melanoma-associated antigen. , 1983, Journal of immunology.

[31]  S. Rosenberg,et al.  Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. , 1981, Cancer research.

[32]  D. Galloway,et al.  Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. , 1981, Hybridoma.

[33]  J. Brown,et al.  Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. , 1981, Proceedings of the National Academy of Sciences of the United States of America.